SIBO

Herbal Therapy for SIBO: A Critical Update for Clinicians

Yoon Hang Kim MD Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

About Dr. Kim

Dr. Yoon Hang Kim is a board-certified preventive medicine physician with over 20 years of clinical experience in integrative and functional medicine. A University of Arizona/Andrew Weil fellowship-trained practitioner, he holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. He specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of eight books — including MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon — and more than 25 peer-reviewed articles. He is the founder of the LDN Support Group.

Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Abstract

The 2014 Chedid et al. retrospective study — comparing herbal antimicrobial therapy with rifaximin for small intestinal bacterial overgrowth (SIBO) — has remained the primary evidence cited for botanical approaches to this condition. Since its publication, several important developments have materially advanced the evidence base. The BRIEF-SIBO trial (Peking University Third Hospital) produced the first prospective, randomized head-to-head comparison of berberine versus rifaximin, with an interim analysis at DDW 2024 reporting non-inferiority of berberine. Redondo-Cuevas et al. (2024) conducted a randomized clinical trial demonstrating that herbal and probiotic adjuncts to rifaximin improved clinical symptoms in methane-dominant SIBO, even without significant changes in breath-test gas levels. Min et al. (2024) published an open-label polyherbal protocol study with gut-skin axis endpoints, and Johns Hopkins has now opened a placebo-controlled pilot trial of a commercial botanical formulation (Biocidin REMOVE, NCT07768267). A 2025 Bayesian network meta-analysis of 30 randomized controlled trials (Zhang et al.) ranked berberine as the highest-efficacy monotherapy for uncomplicated SIBO (SUCRA 82.5%), above rifaximin (57.5%). This article critically evaluates each of these studies, examines the pharmacological mechanisms underlying the key botanical agents (berberine, carvacrol, thymol), contextualizes the evidence within current ACG and AGA guideline positions, and addresses the recurrence problem that limits all SIBO eradication strategies regardless of antimicrobial choice. The evidence trajectory now supports herbal antimicrobials as a legitimate component of SIBO management — though important questions about standardization, long-term safety, durability, and head-to-head comparisons at standard rifaximin doses remain open.

Important: This article is for educational and informational purposes only. It is not medical advice, legal advice, or a substitute for professional consultation. The author is not an attorney. All information presented is derived from publicly available, peer-reviewed literature and publicly registered clinical trials. No product endorsement is intended or implied. Mention of specific commercial products reflects the published study designs and does not constitute a recommendation. Readers should consult their own physician before making any changes to their treatment and their own legal counsel for any questions regarding regulatory, liability, or compliance matters. Use of any information in this article is at the reader's own risk.

The 2014 Chedid Study: What It Showed, What It Didn't, and Why It Still Dominates the Conversation

In 2014, Victor Chedid and colleagues at Johns Hopkins published a retrospective chart review comparing herbal antimicrobial therapy with rifaximin for SIBO eradication. That paper — titled "Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth" — has been cited more than any other study on botanical SIBO treatment. It remains the single most influential piece of evidence driving clinical interest in herbal antimicrobials for this condition.

The findings were genuinely interesting. Among 104 patients with positive lactulose breath tests, 46% of the herbal group (17 of 37) and 34% of the rifaximin group (23 of 67) normalized their breath tests after four weeks of treatment. After adjustment for age, sex, SIBO risk factors, and IBS status, the odds ratio was 1.85 (CI 0.77–4.41, P = .17). Among rifaximin nonresponders offered herbal rescue therapy, 57% (8 of 14) subsequently normalized, compared with 60% (6 of 10) on triple-antibiotic rescue.

However, it is critical to understand what the study did not establish. The difference between groups was not statistically significant. No formal equivalence margin was prespecified. Patients self-selected their treatment, introducing uncontrolled confounding. More than half of screened patients were excluded from the final analysis. Symptom outcomes were not measured with a validated instrument. Two different herbal combinations were pooled into one arm. And the paper contains several internal reporting inconsistencies.

The honest interpretation: Chedid et al. generated a hypothesis worth pursuing. They did not prove equivalence. They demonstrated that certain multi-ingredient botanical regimens were associated with breath-test normalization at a rate that appeared roughly comparable to rifaximin — but the study was too small, too uncontrolled, and too limited in its endpoints to say more than that.

For a decade, that single retrospective study has been the load-bearing wall of clinical arguments for herbal SIBO therapy. What has changed since 2014 is that the wall now has company.

The BRIEF-SIBO Trial: The First Prospective Head-to-Head Comparison

The most significant methodological advance since Chedid is the BRIEF-SIBO study (Berberine and Rifaximin Effects for Small Intestinal Bacterial Overgrowth), an investigator-initiated, open-label, two-arm randomized controlled trial conducted at Peking University Third Hospital in Beijing. Published as a protocol in Frontiers in Pharmacology (Guo et al. 2023), this trial directly compared berberine 400 mg twice daily against rifaximin 400 mg twice daily for two weeks, with breath testing and symptom assessment at two and six weeks.

The primary hypothesis was non-inferiority: that berberine is not inferior to rifaximin for SIBO eradication. This is a fundamentally different question than Chedid asked. Rather than a retrospective observation, this was a prospective comparison with predefined outcomes, randomized allocation, and structured follow-up.

An interim analysis presented at Digestive Disease Week (DDW) 2024 (Duan et al., Gastroenterology 2024;166(5):S-1174) reported that berberine was not inferior to rifaximin for SIBO eradication. That result, while preliminary and from an interim readout rather than the final publication, represents a meaningful step forward in evidence quality.

Two observations from secondary analyses deserve particular attention. First, rifaximin appeared to show more rapid bacterial relapse between weeks two and six, as measured by breath-test curves, while berberine maintained more stable negative breath-test results over the follow-up period. Second, the symptom profiles differed: rifaximin primarily improved bowel frequency and consistency, while berberine appeared to resolve distension and bloating more effectively at the six-week assessment.

Limitations remain real. The trial was open-label and single-center. The interim results have been presented at a conference but (as of November 2026) the full trial has not been published in a peer-reviewed journal with complete data tables and methodology scrutiny. The dose of rifaximin used (800 mg/day) was lower than the 1,200–1,650 mg/day commonly used in North American practice for SIBO, raising questions about generalizability to Western dosing conventions.

Nevertheless, BRIEF-SIBO is the first trial to approach the berberine-versus-rifaximin question with prospective, randomized methodology. Its interim findings are consistent with the Chedid signal — and substantially strengthen the case for a properly powered, multicenter RCT.

Redondo-Cuevas 2024: Herbal Adjuncts to Rifaximin

A separate question — whether adding herbal antimicrobials, probiotics, and prebiotics to standard rifaximin-based therapy improves outcomes — was addressed by Redondo-Cuevas et al. in a randomized clinical trial published in Nutrients (2024;16(7):1083).

This study enrolled 179 patients diagnosed with SIBO by breath testing. The control group received standard antibiotic therapy (rifaximin 200 mg three times daily for 10 days) plus a low-FODMAP diet. The intervention group received the same antibiotic-diet backbone plus herbal antimicrobials with antibiotic properties, probiotics (Saccharomyces boulardii 250 mg/day), glutamine, and prebiotic fiber.

The headline finding: adjunctive herbal supplements and probiotics did not significantly change breath-test gas levels compared with antibiotics alone. However, clinical remission rates were higher in the intervention group, particularly among patients with methane-dominant SIBO (CH₄-SIBO), where gastrointestinal symptom severity scores showed meaningful improvement.

This is a clinically important dissociation. The breath test — widely used as the primary endpoint in SIBO trials — did not move, but the patients felt meaningfully better. That pattern raises a question that applies broadly across the SIBO treatment literature: Are we measuring the right thing? Breath-test normalization and clinical improvement may not travel together as reliably as trial designs assume.

The study's limitations include a relatively short antibiotic course (10 days of rifaximin at 1,200 mg/day rather than the 14-day course more commonly used in many practices), the absence of a gold-standard method for unambiguous breath-test classification, and the multicomponent intervention arm that makes it impossible to attribute any benefit to a single agent.

Still, Redondo-Cuevas contributes a genuinely novel data point: herbal and probiotic adjuncts may improve patient-reported outcomes even when breath-test metrics remain unchanged — and this effect may be particularly relevant in methane-dominant presentations, which are often the most clinically stubborn.

Min 2024: A Polyherbal Protocol With Gut-Skin Axis Data

An open-label prospective study by Min et al. (Nutrients 2024;16(18):3149) explored whether a specific polyherbal protocol — Biocidin liquid tincture plus GI Detox+ binder, with the addition of the olive-leaf polyphenol formula Olivirex for nonresponders — could clear SIBO and simultaneously improve facial erythema associated with rosacea. This design reflected the growing clinical interest in the gut-skin axis and the observation that SIBO and rosacea frequently co-occur.

Of 33 patients screened with breath testing, 19 had confirmed SIBO. Sixteen enrolled; four dropped out after baseline, leaving 12 completing the protocol. Participants received 10 weeks of the botanical regimen; those with persistently positive breath tests received an additional four weeks with the Olivirex addition.

Hydrogen-dominant SIBO responded most consistently: 42.8% of hydrogen-positive participants and 66.7% of hydrogen sulfide-positive participants had negative breath tests by week 10. Facial erythema also decreased measurably. The botanical regimen appeared most effective for hydrogen and hydrogen sulfide subtypes, with methane-dominant SIBO showing less response — a subtype-specific pattern that mirrors what is seen with rifaximin.

The study measured microbiome changes and intestinal permeability markers alongside breath testing and skin outcomes, making it one of the few herbal SIBO trials to attempt objective biological endpoints beyond the breath test itself.

However, the limitations are substantial: no control group, very small sample size (12 completers), open-label design, and the multi-ingredient regimen that prevents attribution to any specific botanical. These are hypothesis-generating findings, not confirmatory evidence.

Notably, Johns Hopkins University has now opened a randomized, double-blind, placebo-controlled pilot feasibility trial of Biocidin REMOVE (a formulated capsule version) for SIBO in patients with IBS (NCT07768267, registered August 2026). This is a 40-participant study with 1:1 randomization, breath-test endpoints, stool microbiome analysis, and standardized symptom assessment. It represents the first placebo-controlled academic trial of a specific commercial polyherbal product for SIBO — a meaningful step toward the kind of rigorous evidence the field needs.

The 2025 Network Meta-Analysis: Ranking SIBO Treatments Across 30 Trials

The most comprehensive synthesis to date was published by Zhang et al. in Therapeutic Advances in Gastroenterology (2025;18:17562848251399033). This Bayesian network meta-analysis pooled data from 30 RCTs involving 1,552 patients across multiple therapeutic classes: rifaximin, other antibiotics (quinolones, aminoglycosides, metronidazole, tetracyclines), berberine, probiotics, prokinetic agents, and combination regimens.

The SUCRA (Surface Under the Cumulative Ranking Curve) analysis established a clear efficacy hierarchy for overall SIBO eradication. Berberine ranked highest at 82.5%, followed by combination treatment options (72.5%), rifaximin plus a prokinetic agent (66.9%), quinolones (64.0%), aminoglycosides (59.4%), rifaximin alone (57.5%), probiotics (55.3%), and prokinetics alone trailing the field.

In the subgroup of patients with uncomplicated SIBO (no concurrent functional gastrointestinal disorders or liver disease), berberine's lead held: SUCRA 79.4% versus rifaximin at 48.8%. For SIBO with concurrent functional gastrointestinal disorders, the combination of rifaximin plus a prokinetic ranked highest (SUCRA 89%). For SIBO with chronic liver disease, prokinetic therapy alone ranked most favorably (SUCRA 79.6%).

Direct pairwise comparisons showed that berberine, rifaximin plus prokinetic, quinolones, and aminoglycosides all showed numerically superior efficacy to rifaximin alone, though none reached statistical significance in head-to-head comparisons. Rifaximin was significantly superior to metronidazole (RR 1.54; 95% CI 1.17–2.02) and to placebo (RR 2.43; 95% CI 1.32–4.45).

The clinical takeaway is notable: in a network analysis including all available RCT evidence, berberine — not rifaximin — ranked as the single most effective monotherapy for uncomplicated SIBO. This does not mean berberine is proven superior. SUCRA rankings are probabilistic summaries, not definitive proof of superiority, and the berberine evidence base is still thinner than rifaximin's. But it does mean that the hypothesis generated by Chedid in 2014 is now being corroborated by converging lines of evidence at a higher level of synthesis.

The context-dependent rankings also deserve emphasis. For patients with concurrent IBS or other functional GI disorders, rifaximin combined with a prokinetic appeared most effective — suggesting that motility support may matter as much as antimicrobial choice in this subpopulation. For patients with chronic liver disease, prokinetics alone outranked antibiotics. The message is that SIBO treatment may need to be stratified by clinical context rather than approached with a single default regimen.

Mechanisms of Action: Why These Botanicals Are Not Arbitrary Choices

The herbal regimens studied in SIBO trials are not random collections of plants. The key active compounds — berberine, carvacrol, and thymol — have well-characterized antimicrobial mechanisms that distinguish them from the "throw herbs at it" caricature that mainstream gastroenterology sometimes assigns to botanical approaches.

Berberine

Berberine is an isoquinoline alkaloid found in Coptis, Berberis, Hydrastis (goldenseal), and Phellodendron species. Its pharmacology operates through multiple convergent pathways.

The most extensively studied mechanism is activation of AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation in enterocytes modulates cellular energy metabolism, enhances glucose uptake via GLUT4 translocation, and suppresses hepatic gluconeogenesis — mechanisms that also underlie berberine's well-documented hypoglycemic effects (the reason it is often called "nature's metformin").

As an antimicrobial, berberine inhibits bacterial cell division by disrupting FtsZ assembly — the protein ring required for bacterial cytokinesis. It demonstrates broad-spectrum activity against Gram-positive and Gram-negative bacteria, fungi, and some protozoa. Critically, berberine also suppresses the NF-κB and MAPK inflammatory signaling cascades, reducing transcription of TNF-α, IL-1β, and IL-6. This dual antimicrobial-anti-inflammatory profile is mechanistically distinct from rifaximin's purely antimicrobial action.

Berberine's low oral bioavailability — often cited as a limitation — may actually be an advantage for SIBO treatment. Because the compound concentrates in the gut lumen rather than achieving high systemic levels, it exerts potent local antimicrobial effects in the intestinal tract while limiting systemic exposure. Recent evidence suggests that berberine modulates gut microbiome composition in ways that favor beneficial organisms: enhancing short-chain fatty acid production, supporting Akkermansia muciniphila populations (a keystone species for gut barrier integrity), and reducing endotoxemia.

Carvacrol and Thymol

Carvacrol (the dominant phenolic in oregano oil, typically comprising 60–80% of the essential oil) and thymol (its structural isomer, dominant in thyme oil) act through direct disruption of bacterial cell membranes. These lipophilic phenols partition into the lipid bilayer, increase membrane permeability, cause leakage of intracellular contents, and ultimately lyse the bacterial cell.

In vitro studies consistently demonstrate broad-spectrum antibacterial activity against both Gram-positive and Gram-negative organisms, with minimum inhibitory concentrations in the range of 0.005–1 mg/mL depending on the organism and the oil source. Carvacrol also inhibits bacterial biofilm formation and disrupts efflux pump function — two resistance mechanisms that make chronic infections difficult to treat.

Recent synergy studies (2025) have demonstrated that carvacrol combined with conventional antibiotics (notably tobramycin) produces highly synergistic effects, with fractional inhibitory concentration indices as low as 0.125 against MRSA. This is not directly applicable to SIBO treatment, but it illustrates a mechanistic principle: phenolic antimicrobials from oregano may potentiate other antimicrobial agents through membrane disruption.

One important caveat: oregano oil is a broad-spectrum antimicrobial that does not selectively target pathogenic organisms. Prolonged use (beyond approximately six weeks) carries a theoretical risk of secondary dysbiosis — a concern that has not been systematically studied in SIBO patients but deserves clinical attention.

The Combination Rationale

The Chedid study and subsequent herbal SIBO protocols use multi-ingredient combinations precisely because the mechanisms are complementary. Berberine inhibits cell division and modulates inflammation. Carvacrol and thymol disrupt membranes and biofilms. Other ingredients in commercial formulations (wormwood, lemon balm, olive leaf) contribute additional antimicrobial and anti-inflammatory activity. The theoretical advantage over monotherapy is coverage of multiple bacterial targets through different mechanisms — conceptually similar to combination antibiotic therapy, but with plant-derived agents.

What the Guidelines Say — and Don't Say

The ACG Clinical Guideline on Small Intestinal Bacterial Overgrowth (Pimentel et al., American Journal of Gastroenterology 2020;115(2):165–178) recommends rifaximin 550 mg three times daily as the primary antibiotic treatment. It does not address herbal therapy. The AGA guideline similarly centers on rifaximin, with a focus on dietary modification (low-FODMAP, Specific Carbohydrate Diet) as adjunctive intervention. Neither guideline endorses or formally evaluates botanical antimicrobials.

This absence is not a rejection of efficacy. It reflects the evidence threshold that guideline committees apply: they require randomized, controlled, adequately powered trials with validated symptom outcomes to make a formal recommendation. As of the 2020 guideline cycle, no herbal SIBO trial met that standard. The Chedid study was retrospective and uncontrolled. The BRIEF-SIBO trial had not yet reported. The Redondo-Cuevas and Min studies had not yet been published.

The practical consequence is a disconnect between guideline recommendations and clinical reality. In integrative and functional medicine practices, herbal antimicrobials are used routinely — often as first-line therapy, sometimes as rescue after rifaximin failure. The clinical experience base is substantial, even if the trial evidence has lagged behind.

The 2025 Zhang et al. network meta-analysis included only RCTs, and its SUCRA rankings placed berberine above rifaximin for uncomplicated SIBO. If the BRIEF-SIBO final publication and the Johns Hopkins Biocidin pilot produce positive results, the next guideline cycle may face pressure to formally address herbal therapy — at minimum as a conditional recommendation for patients who decline, cannot tolerate, or have failed antibiotic treatment.

In the meantime, the honest position for clinicians is this: herbal antimicrobials are not yet guideline-endorsed, and there are legitimate methodological reasons for that. But the evidence trajectory is moving in a clear direction, and dismissing herbal therapy as lacking any evidence base is no longer accurate.

The Recurrence Problem: Why Eradication Alone Fails

The most important lesson from the SIBO treatment literature — herbal and pharmaceutical alike — is that eradication is not enough. Recurrence rates range from 13% at three months to 44% at nine months in published studies, with older age, constipation-predominant presentation, history of appendectomy, and chronic PPI use all increasing the probability of relapse.

The pathophysiological driver of recurrence in many patients is dysfunction of the migrating motor complex (MMC), the cyclical pattern of electrical activity that sweeps the small intestine during fasting. Phase III of the MMC functions as the intestinal "housekeeper," clearing residual bacteria and debris toward the colon between meals. When this mechanism is impaired — whether from post-infectious autoimmunity (anti-vinculin and anti-CdtB antibodies), diabetic neuropathy, hypothyroidism, scleroderma, chronic opioid use, or other causes — the small intestine loses its primary defense against bacterial accumulation.

This recognition has driven growing interest in prokinetic agents as maintenance therapy after SIBO eradication. Published data show that prokinetic prevention significantly extends the symptom-free interval. In one study, patients receiving no prevention after successful antibiotic therapy experienced symptom recurrence after approximately 60 days, while tegaserod extended remission to approximately 242 days (P = .003 versus no prevention). Low-dose erythromycin showed an intermediate effect at approximately 139 days.

The 2025 Zhang et al. network meta-analysis corroborates the prokinetic signal from a different angle: for patients with SIBO and concurrent functional gastrointestinal disorders, the combination of rifaximin plus a prokinetic agent ranked highest in efficacy (SUCRA 89%), substantially above rifaximin alone. For patients with SIBO and chronic liver disease, prokinetic therapy alone was the most favorable intervention.

The clinical implication for herbal SIBO therapy is direct. Even if botanical antimicrobials successfully eradicate bacterial overgrowth — and the evidence increasingly suggests they can — recurrence is driven by the same motility deficits regardless of which antimicrobial was used. A clinician who uses herbal antimicrobials for eradication but does not address underlying motility dysfunction, meal spacing, PPI dependency, or other root causes is likely to see the same relapse pattern as one who uses rifaximin and stops.

The emerging model for durable SIBO management is multi-phase: eradication (antimicrobial, herbal, elemental diet, or a combination), followed by motility restoration (pharmaceutical or botanical prokinetics, meal-spacing strategies), root-cause identification (breath-test subtyping, anti-vinculin/anti-CdtB testing, thyroid and motility assessment), and ongoing surveillance.

Clinical Synthesis: What the Evidence Supports — and What Remains Open

What is now supported by converging evidence

Berberine-containing herbal regimens produce SIBO breath-test normalization rates that are in the same range as rifaximin. This is supported by the Chedid retrospective comparison, the BRIEF-SIBO RCT interim analysis, and the 2025 network meta-analysis SUCRA rankings.
Herbal antimicrobials may be effective as rescue therapy after rifaximin failure. The Chedid rescue data (57% response) and the BRIEF-SIBO durability signal (more stable breath tests at six weeks) both point in this direction.
Combination therapy — adding herbal antimicrobials and probiotics to rifaximin — may improve clinical symptoms even when breath-test metrics do not change, particularly in methane-dominant SIBO (Redondo-Cuevas 2024).
The mechanisms of action for the key botanicals (berberine, carvacrol, thymol) are pharmacologically well-characterized and operate through pathways that are complementary to, and distinct from, rifaximin.
SIBO recurrence is driven primarily by motility dysfunction, not by choice of antimicrobial agent. Prokinetic maintenance and root-cause identification are essential regardless of whether eradication uses pharmaceutical or botanical agents.

What is not yet established

No placebo-controlled, double-blind RCT has yet demonstrated herbal SIBO treatment superiority or equivalence to rifaximin. The BRIEF-SIBO final publication and the Johns Hopkins Biocidin REMOVE trial may address this gap.
Standardized dosing protocols for herbal SIBO treatment have not been validated across products or populations. The specific products used in the Chedid study (Candibactin-AR/BR, Dysbiocide/FC Cidal) are not interchangeable with all "SIBO herbal supplements" on the market.
Long-term safety of repeated herbal antimicrobial courses has not been systematically studied. The theoretical concern about broad-spectrum disruption of beneficial gut flora — particularly with extended oregano oil use — lacks definitive data in either direction.
Microbiome outcomes beyond breath testing (16S sequencing, short-chain fatty acid profiles, intestinal permeability markers) have been measured in only one very small study (Min 2024).
Head-to-head comparisons between herbal therapy and rifaximin at standard North American rifaximin doses (1,650 mg/day for 14 days) have not been published.
Whether herbal antimicrobials produce durable remission or merely temporary breath-test normalization remains unresolved.

Questions that matter for the next generation of evidence

Does berberine's apparent durability advantage (more stable breath tests at six weeks in the BRIEF-SIBO interim data) hold in larger, longer trials?
Is the breath-test/symptom dissociation observed by Redondo-Cuevas reproducible, and does it reflect a meaningful clinical outcome that breath testing misses?
Can herbal prokinetics (ginger, artichoke leaf, 5-HTP) extend remission duration comparably to pharmaceutical prokinetics after botanical eradication?
Does herbal therapy preserve beneficial microbiome diversity better than rifaximin, as has been hypothesized but never measured in a controlled comparison?
Are specific SIBO subtypes (hydrogen-dominant, methane-dominant, hydrogen sulfide-dominant) differentially responsive to specific botanical agents?

Conclusion

The evidence base for herbal antimicrobial therapy in SIBO has undergone a qualitative shift since Chedid et al. first documented breath-test normalization rates comparable to rifaximin in 2014. What was then a single hypothesis-generating retrospective study is now a body of converging evidence: a prospective RCT reporting non-inferiority of berberine, a network meta-analysis of 30 trials ranking berberine as the highest-efficacy monotherapy for uncomplicated SIBO, additional RCT data demonstrating clinical benefit from herbal adjuncts in methane-dominant presentations, and a new academic placebo-controlled trial underway at Johns Hopkins.

None of this constitutes definitive proof. The BRIEF-SIBO final results have not been published. No trial has compared herbal therapy to rifaximin at full North American doses. Long-term safety data from repeated botanical courses are lacking. Product standardization remains an unresolved challenge.

But the trajectory is clear. The question is no longer whether herbal antimicrobials deserve investigation for SIBO — it is how quickly the evidence can reach the threshold that guideline committees require. For clinicians already using these agents, the literature increasingly validates what clinical experience has suggested. For clinicians who have dismissed herbal therapy as unsupported, the data now warrant reconsideration.

What is most important — and what this article emphasizes throughout — is that the choice of antimicrobial agent is only one variable in SIBO management. Eradication without motility restoration, root-cause identification, and recurrence prevention produces temporary results regardless of whether the antimicrobial is pharmaceutical or botanical. The most useful takeaway from the current evidence is not "herbs versus antibiotics" but rather the recognition that durable SIBO management requires a multi-phase strategy in which the antimicrobial — herbal or pharmaceutical — is the beginning, not the end.

Work with Dr. Kim

Dr. Kim offers personalized integrative and functional medicine consultations through his membership-based telemedicine practice, currently serving clients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. He also practices at Hill Country Integrative Medicine in Fredericksburg, Texas, where he provides in-person consultation, IV nutrition therapy, functional medicine testing, and specialty acupuncture.

For more information or to schedule a consultation: